Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.
Identifieur interne : 000B32 ( PubMed/Checkpoint ); précédent : 000B31; suivant : 000B33Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.
Auteurs : Sébastien Robert Montel [France] ; Catherine BungenerSource :
- Surgical neurology [ 1879-3339 ] ; 2009.
English descriptors
- KwdEn :
- Adaptation, Psychological, Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Anxiety (etiology), Cognition, Deep Brain Stimulation (adverse effects), Depression (etiology), Dopamine Agonists (therapeutic use), Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson Disease (therapy), Patient Education as Topic, Psychomotor Performance, Quality of Life, Severity of Illness Index, Surveys and Questionnaires, Time Factors.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- adverse effects : Deep Brain Stimulation.
- drug therapy : Parkinson Disease.
- etiology : Anxiety, Depression.
- psychology : Parkinson Disease.
- therapy : Parkinson Disease.
- Adaptation, Psychological, Adult, Aged, Aged, 80 and over, Cognition, Female, Humans, Male, Middle Aged, Patient Education as Topic, Psychomotor Performance, Quality of Life, Severity of Illness Index, Surveys and Questionnaires, Time Factors.
Abstract
Although the positive effect of DBS of the STN on motor signs and mobility in PD is indisputable, the effect on mental health (depression and anxiety) as well as on QoL is subject to more debate. Some works have already shown that coping strategies have an impact on QoL, depression, and anxiety. To date, no studies have examined the coping strategies used by patients with PD who undergo STN stimulation. We decided to investigate the coping strategies of patients with PD who have undergone an STN DBS and their relationship with QoL while taking depression and anxiety into account.
DOI: 10.1016/j.surneu.2008.05.026
PubMed: 18786708
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18786708Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.</title><author><name sortKey="Montel, Sebastien Robert" sort="Montel, Sebastien Robert" uniqKey="Montel S" first="Sébastien Robert" last="Montel">Sébastien Robert Montel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Clinical Psychopathology and Neuropsychology, University Paris Descartes, France. montel.sebastien@wanadoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Clinical Psychopathology and Neuropsychology, University Paris Descartes</wicri:regionArea><wicri:noRegion>University Paris Descartes</wicri:noRegion><wicri:noRegion>University Paris Descartes</wicri:noRegion></affiliation></author><author><name sortKey="Bungener, Catherine" sort="Bungener, Catherine" uniqKey="Bungener C" first="Catherine" last="Bungener">Catherine Bungener</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:18786708</idno><idno type="pmid">18786708</idno><idno type="doi">10.1016/j.surneu.2008.05.026</idno><idno type="wicri:Area/PubMed/Corpus">000B75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B75</idno><idno type="wicri:Area/PubMed/Curation">000B35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B35</idno><idno type="wicri:Area/PubMed/Checkpoint">000B35</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.</title><author><name sortKey="Montel, Sebastien Robert" sort="Montel, Sebastien Robert" uniqKey="Montel S" first="Sébastien Robert" last="Montel">Sébastien Robert Montel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Clinical Psychopathology and Neuropsychology, University Paris Descartes, France. montel.sebastien@wanadoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Clinical Psychopathology and Neuropsychology, University Paris Descartes</wicri:regionArea><wicri:noRegion>University Paris Descartes</wicri:noRegion><wicri:noRegion>University Paris Descartes</wicri:noRegion></affiliation></author><author><name sortKey="Bungener, Catherine" sort="Bungener, Catherine" uniqKey="Bungener C" first="Catherine" last="Bungener">Catherine Bungener</name></author></analytic><series><title level="j">Surgical neurology</title><idno type="eISSN">1879-3339</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Psychological</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Anxiety (etiology)</term><term>Cognition</term><term>Deep Brain Stimulation (adverse effects)</term><term>Depression (etiology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson Disease (therapy)</term><term>Patient Education as Topic</term><term>Psychomotor Performance</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anxiety</term><term>Depression</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adaptation, Psychological</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cognition</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Education as Topic</term><term>Psychomotor Performance</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the positive effect of DBS of the STN on motor signs and mobility in PD is indisputable, the effect on mental health (depression and anxiety) as well as on QoL is subject to more debate. Some works have already shown that coping strategies have an impact on QoL, depression, and anxiety. To date, no studies have examined the coping strategies used by patients with PD who undergo STN stimulation. We decided to investigate the coping strategies of patients with PD who have undergone an STN DBS and their relationship with QoL while taking depression and anxiety into account.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18786708</PMID><DateCreated><Year>2009</Year><Month>07</Month><Day>17</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3339</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Surgical neurology</Title><ISOAbbreviation>Surg Neurol</ISOAbbreviation></Journal><ArticleTitle>Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.</ArticleTitle><Pagination><MedlinePgn>105-10; discussion 110-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.surneu.2008.05.026</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although the positive effect of DBS of the STN on motor signs and mobility in PD is indisputable, the effect on mental health (depression and anxiety) as well as on QoL is subject to more debate. Some works have already shown that coping strategies have an impact on QoL, depression, and anxiety. To date, no studies have examined the coping strategies used by patients with PD who undergo STN stimulation. We decided to investigate the coping strategies of patients with PD who have undergone an STN DBS and their relationship with QoL while taking depression and anxiety into account.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 40 patients stimulated for 12 months and 40 patients under dopatherapy were compared. The 2 groups were matched according to age, sex, age at disease onset, severity of disease, motor scores, daily treatment dosage, and professional status. Semistructured interviews were carried out, after which, their mental and cognitive states were assessed using different scales (MINI, MADRS, EHD, HAMA, FAB). Finally, all subjects completed 3 self-report questionnaires: 2 assessing coping strategies (WCC, CHIP), and 1, QoL the Parkinson Disease Questionnaire (PDQ-39).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Depression and anxiety were not significantly influenced by the type of treatment. Concerning coping strategies, we found a significant effect of the stimulation on instrumental strategies with higher scores for patients under dopatherapy. As for QoL, the only difference concerned communication with a poorer QoL for stimulated patients. We noted no significant correlations between any coping strategies and all of the dimensions of QoL in the stimulated group, whereas we found the opposite result for the dopatherapy group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results encourage us to prepare patient candidates for such stimulation by developing interventions focused first on their expectations and second, on their coping strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montel</LastName><ForeName>Sébastien Robert</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Psychopathology and Neuropsychology, University Paris Descartes, France. montel.sebastien@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bungener</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Neurol</MedlineTA><NlmUniqueID>0367070</NlmUniqueID><ISSNLinking>0090-3019</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="Y">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>05</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18786708</ArticleId><ArticleId IdType="pii">S0090-3019(08)00588-0</ArticleId><ArticleId IdType="doi">10.1016/j.surneu.2008.05.026</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Bungener, Catherine" sort="Bungener, Catherine" uniqKey="Bungener C" first="Catherine" last="Bungener">Catherine Bungener</name></noCountry><country name="France"><noRegion><name sortKey="Montel, Sebastien Robert" sort="Montel, Sebastien Robert" uniqKey="Montel S" first="Sébastien Robert" last="Montel">Sébastien Robert Montel</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18786708
|texte= Coping and quality of life of patients with Parkinson disease who have undergone deep brain stimulation of the subthalamic nucleus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18786708" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |